NeoGenomics Inc (NEO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NeoGenomics Inc (NEO) has a cash flow conversion efficiency ratio of 0.025x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($19.96 Million) by net assets ($786.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NEO stock market capitalisation for the company's overall valuation and market capitalisation.
NeoGenomics Inc - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how NeoGenomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NeoGenomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeoGenomics Inc ranked by their cash flow conversion efficiency. Explore NEO operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metcash Ltd
AU:MTS
|
0.157x |
|
BGI Genomics Co Ltd
SHE:300676
|
0.000x |
|
China Railway Hi-tech Industry Corp Ltd
SHG:600528
|
0.101x |
|
Ningbo Zhenyu Technology Co. Ltd.
SHE:300953
|
0.016x |
|
The Andersons Inc
NASDAQ:ANDE
|
0.359x |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
0.009x |
|
OPERAD.D.SIT.MEX.A1 -01
F:98Y
|
0.040x |
|
Park Hotels & Resorts Inc
NYSE:PK
|
0.019x |
Annual Cash Flow Conversion Efficiency for NeoGenomics Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of NeoGenomics Inc from 2000 to 2025. View NeoGenomics Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $836.56 Million | $5.23 Million | 0.006x | -19.68% |
| 2024-12-31 | $902.34 Million | $7.02 Million | 0.008x | +475.22% |
| 2023-12-31 | $941.54 Million | $-1.95 Million | -0.002x | +96.86% |
| 2022-12-31 | $998.02 Million | $-65.99 Million | -0.066x | -174.23% |
| 2021-12-31 | $1.11 Billion | $-26.72 Million | -0.024x | -1246.64% |
| 2020-12-31 | $694.29 Million | $1.46 Million | 0.002x | -95.43% |
| 2019-12-31 | $507.41 Million | $23.37 Million | 0.046x | -67.05% |
| 2018-12-31 | $320.44 Million | $44.79 Million | 0.140x | +59.26% |
| 2017-12-31 | $205.53 Million | $18.04 Million | 0.088x | -23.75% |
| 2016-12-31 | $186.60 Million | $21.48 Million | 0.115x | +328.69% |
| 2015-12-31 | $238.11 Million | $6.39 Million | 0.027x | -82.84% |
| 2014-12-31 | $60.41 Million | $9.45 Million | 0.156x | +52.52% |
| 2013-12-31 | $21.71 Million | $2.23 Million | 0.103x | +292.14% |
| 2012-12-31 | $9.22 Million | $-492.00K | -0.053x | -556.25% |
| 2011-12-31 | $5.90 Million | $69.00K | 0.012x | +101.79% |
| 2010-12-31 | $3.13 Million | $-2.05 Million | -0.655x | -146.19% |
| 2009-12-31 | $5.64 Million | $-1.50 Million | -0.266x | -188.57% |
| 2008-12-31 | $1.50 Million | $-138.31K | -0.092x | +91.90% |
| 2007-12-31 | $2.32 Million | $-2.64 Million | -1.138x | +91.06% |
| 2006-12-31 | $54.51K | $-693.78K | -12.727x | -1503.72% |
| 2005-12-31 | $-994.94K | $-902.05K | 0.907x | -41.22% |
| 2004-12-31 | $-426.65K | $-658.13K | 1.543x | +6.57% |
| 2003-12-31 | $-367.80K | $-532.37K | 1.447x | +108.78% |
| 2002-12-31 | $23.34K | $-384.80K | -16.483x | -2333.16% |
| 2001-12-31 | $-104.87K | $-77.41K | 0.738x | -47.98% |
| 2000-12-31 | $-124.84K | $-177.13K | 1.419x | -- |
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to dise… Read more